Why Protein Degraders Fail to Degrade Their Targets: Common Causes and Solutions

* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.

Consult with Our Experts

What Counts as a Degradation Failure?

A protein degrader can bind its target tightly, look clean in biochemical assays, and still produce no measurable loss of protein in cells. This is one of the most common frustrations in targeted protein degradation (TPD) programs, and it is rarely caused by a single mistake. Degradation is a chain of events—cell entry, target engagement, E3 ligase recruitment, ternary complex formation, ubiquitin transfer, and proteasome processing—and the chain is only as strong as its weakest link.

The practical implication is that "no degradation" is a symptom, not a diagnosis. Before synthesizing more analogs, it is worth defining precisely what failed, because the corrective action for an exposure problem is almost the opposite of the corrective action for a ternary complex problem. This article walks through the failure modes in the order in which they occur along the degradation pathway, and gives the experimental checks that distinguish one from another.

I. Binding Affinity Versus Degradation Efficiency: Why Engagement Is Not Enough

The core distinction: inhibitors are occupancy-driven, degraders are event-driven. An inhibitor works by staying bound; a degrader works by briefly bringing two proteins together and triggering a catalytic, repeatable ubiquitination event. Strong binary binding is therefore a necessary condition, not a sufficient one.

Why this misleads teams: a warhead that binds a target with nanomolar affinity can be converted into a degrader that shows no activity at all, because the added E3 ligand and linker change the molecule's shape, properties, and the geometry of the complex it forms. Published analyses of promiscuous kinase-binding degraders have shown the reverse asymmetry as well: some kinases engaged with high affinity are not degraded, while others bound only modestly are degraded efficiently. Binding and degradation are simply different readouts, and the comparison between PROTACs and traditional small molecule inhibitors makes the point clearly.

What to do: treat target affinity as one input among several. If the conjugated warhead retains binding but the degrader is inactive, the limitation lies downstream of engagement—in exposure, E3 biology, or complex geometry—and additional affinity optimization will not fix it.

II. DC₅₀, D_max, and Degradation Kinetics: The Readouts That Define Success

Why definitions matter: many "failures" are actually misread curves. A degrader profile is described by at least four parameters, and each one fails for a different reason. Learning to read them separately is the fastest way to locate the problem.

Table 1. Degradation Readouts and What a Failing Profile Usually Indicates.

Practical rule: report DC₅₀, D_max, time course, and recovery together. A compound with a modest DC₅₀ but a D_max above 90% is often a better starting point than one with an apparently better DC₅₀ that plateaus at 40%, because high D_max indicates that the productive complex does form and the remaining work is optimization rather than re-design.

III. Apparent Failure Versus True Failure: Ruling Out Experimental Artifacts

Cytotoxicity masquerading as degradation: if compound treatment reduces cell health, total protein content per well falls and the target band appears lighter. Normalizing to a loading control measured in the same lane helps, but a parallel viability readout is the more reliable guard.

Detection problems: antibody quality, epitope masking after compound binding, saturation of the signal at high target abundance, and inconsistent loading all produce apparent changes in protein level that have nothing to do with degradation.

Compound handling: precipitation upon dilution into aqueous medium, adsorption to plasticware, and DMSO sensitivity can lower the effective concentration by orders of magnitude, making an active compound look inactive.

How to confirm a true result: repeat with an orthogonal readout, use a matched inactive control at the same concentration, and check that the effect is reversed by proteasome inhibition and by competition with free E3 ligand. Degradation that survives these three checks is real.

Compound Exposure Failures: The Degrader Never Reaches Its Target

Before changing the target ligand or E3 recruiter, establish whether enough intact degrader reaches the relevant cellular compartment. The concentration added to a culture well is not necessarily the concentration available to bind the target. Even a substantial amount recovered from a cell pellet can include membrane-associated or otherwise sequestered material.

I. Poor Membrane Permeability and Low Intracellular Concentration

Some bifunctional degraders cross membranes poorly because of their size, polarity, hydrogen-bonding pattern, or conformational behavior. However, molecular weight alone is not a reliable predictor. Linker-dependent folding can change how much polar surface is exposed, allowing closely related compounds to have different permeability profiles.

• Check: Compare biochemical binding with cellular target engagement. Measure intact compound accumulation over time using LC-MS/MS, with washing, extraction recovery, and extracellular carryover controls. Add a passive permeability assay when it will help distinguish diffusion from cell-specific transport effects.
• Interpret: Weak cellular engagement despite retained biochemical binding supports an exposure problem, but does not identify its cause. Total cell-associated concentration should not be presented as the free concentration at the target.
• Improve: Test matched changes to linker polarity, hydrogen-bond donors, ionization, or conformational flexibility. Recheck solubility and target engagement alongside permeability so that improving membrane passage does not introduce another limitation.

A PROTAC cellular permeability assay can help distinguish limited cellular entry from downstream recruitment or degradation problems.

II. Low Solubility, Aggregation, and Nonspecific Binding

A clear concentrated stock does not prove that the compound remains dissolved after dilution into assay medium. Precipitation, colloidal aggregation, adsorption to labware, and binding to medium components can reduce the freely available fraction. Aggregation is also medium-dependent, so behavior in a simple buffer should not be assumed to represent behavior in serum-containing cultures.

• Check: Measure dissolved compound and recovery in the actual assay medium across the intended concentration range and incubation period. Investigate turbidity, particulate material, and concentration-dependent losses rather than relying only on visual inspection.
• Interpret: Low recovery suggests an exposure or handling issue, but requires controls to distinguish precipitation, adsorption, and chemical decomposition. A high nominal dose cannot compensate reliably for an unknown dissolved concentration.
• Improve: Refine stock preparation, dilution order, and storage conditions. Keep vehicle content consistent. Where needed, compare less aggregation-prone analogs while confirming that the revised assay conditions preserve cell health and target biology.

Combining solubility and stability evaluation with cellular testing helps prevent formulation-related losses from being mistaken for weak degrader chemistry.

III. Efflux Transporters and Sequestration in Off-Target Compartments

Cellular entry does not guarantee sustained access to the target. Transporters can export a degrader after uptake, and intracellular partitioning can separate accumulated compound from the protein pool of interest. ABCB1/MDR1 and ABCC1/MRP1 have been experimentally linked to reduced sensitivity to selected PROTACs; transporter involvement remains compound- and cell-dependent.

• Check: Compare uptake and washout profiles in responsive and poorly responsive cells. Where transporter involvement is suspected, combine expression analysis with a suitable genetic perturbation or controlled inhibitor experiment.
• Interpret: Increased engagement and degradation after reducing transporter activity supports an efflux contribution. Expression alone is insufficient evidence. Likewise, strong fluorescence does not prove useful exposure when a labeled analog accumulates away from the target.
• Improve: Prioritize analogs with lower demonstrated efflux liability. Investigate compartmental partitioning when total accumulation and target engagement disagree, and confirm that any label used for imaging has not changed compound behavior.

IV. Metabolic Instability and Short Intracellular Residence Time

A degrader may enter cells but lose activity as the intact molecule disappears. Cleavage can generate fragments that retain target affinity but no longer recruit the ligase. In one experimental degrader series, linker metabolism produced target-binding metabolites that competed with the intact degrader and limited target depletion.

• Check: Follow intact compound and major breakdown products in medium and cells. Use relevant PROTAC in vitro metabolism studies to investigate suspected metabolic liabilities, rather than assuming that medium instability is enzymatic.
• Interpret: Distinguish intracellular retention from target-binding residence time and ternary-complex lifetime. These are different measurements. A durable degradation response may outlast compound exposure, so rapid compound loss does not automatically mean immediate target recovery.
• Improve: Replace experimentally identified labile groups while preserving productive binding geometry. Compare compound persistence, degradation duration, and target recovery to determine whether improved stability actually addresses the observed limitation.

Table 2. Exposure Measurements and the Questions They Can Answer.

Target-Side Failures: When the Protein of Interest Resists Degradation

Once exposure is supported by evidence, examine the target in its cellular context. Binding to an isolated domain is not equivalent to accessing the full-length protein in a native complex. Different isoforms, locations, interaction partners, and synthesis rates can create distinct degradation responses within the same model.

I. Insufficient Target Engagement Under Cellular Conditions

The parent ligand may bind well while the assembled degrader does not. Conjugation can obstruct important contacts or introduce an unfavorable attachment vector. Cellular binding can also differ from purified-protein measurements because the target adopts different conformations or participates in interactions absent from the biochemical assay.

• Check: Compare the complete degrader with its parent ligand using the same protein construct, then measure engagement in the intended cells. Interpret binding data alongside compound exposure rather than assigning every cellular potency shift to affinity loss.
• Improve: Evaluate alternative attachment sites or target-binding scaffolds. Preserve key binding contacts and establish that the complete molecule still engages the relevant target species before expanding a linker library.

Target ligand binding assays for TPD development can help separate ligand-conjugation problems from later degradation steps. For molecular glues, test induced target recruitment where independent target binding is not the applicable mechanism.

II. Subcellular Localization and Compartmental Inaccessibility

A target can be detectable in whole-cell lysate while its relevant binding region remains inaccessible to the proposed machinery. Nuclear, cytosolic, membrane-associated, and organelle-enclosed pools should therefore be distinguished. Experimental work with compartment-selective E3 recruitment illustrates why the location of the protein pool matters, not simply total target expression.

• Check: Use imaging and fractionation with compartment markers to identify the target pool linked to the research question. For membrane proteins, assess whether the bound region faces the cytosol or an inaccessible lumen.
• Improve: Choose an accessible target-binding region and a compatible degradation route. For genuinely inaccessible pools, consider changing the modality rather than repeatedly increasing concentration or extending treatment.

Target localization analysis for TPD development helps define which protein pool should be measured and which recruitment strategies are physically plausible.

III. Target Resynthesis Outpacing Degradation

Measured target abundance reflects both removal and replacement. A degrader can accelerate destruction while continued synthesis limits net depletion. Feedback-driven expression or recovery after compound loss may therefore produce a shallow plateau or a rebound that appears to be resistance in a late endpoint assay.

• Check: Measure early loss, the lowest target level, and subsequent recovery. Compare protein abundance with transcript changes and, where needed, direct protein synthesis or turnover measurements. Increased transcript abundance alone does not quantify new protein production.
• Improve: Prioritize compounds that sustain sufficient removal over the required observation period. Compare continuous exposure with washout, and distinguish exposure loss from compensatory synthesis before selecting a redesign strategy.

Protein synthesis inhibition may help investigate turnover, but it changes the biological system. A deeper depletion observed only under synthesis blockade should not be presented as the degrader's unassisted performance.

IV. Scaffolding, Complex-Bound, and Aggregated Target Species

Scaffolding activity or complex membership does not automatically make a protein undegradable. The relevant question is whether its binding region, ubiquitination sites, and subsequent processing are accessible in the native state. Proteasomal processing can also depend on target features beyond recruitment: experiments with selected targets have shown that disordered regions influence degradation efficiency.

• Check: Compare soluble and insoluble fractions, assess target interaction partners, and establish whether the assay recovers the protein species of interest. Confirm that an apparent loss from the soluble fraction is not redistribution into an insoluble pool.
• Improve: Test alternative binding domains or E3 orientations when complex-associated shielding is suspected. Where persistent aggregates are the intended target, assess whether the chosen clearance route is appropriate instead of assuming that a conventional soluble-target degrader will work.

Target protein interaction profiling for TPD development can support comparisons between isolated-target results and the behavior of native protein assemblies.

V. Target Mutations and Altered Binding Site Conformation

A sequence change may weaken ligand binding, alter the target-E3 interface, or change the conformation available for recruitment. These effects should be tested separately. Molecular glue studies have identified resistance-associated changes both at recruitment interfaces and at more distant positions, demonstrating that pocket inspection alone may be insufficient.

• Check: Confirm the target sequence and isoform in the experimental model. Compare relevant variants for engagement, recruitment, ubiquitination, and degradation while controlling for expression differences.
• Improve: Change the target ligand when binding is impaired, or explore a different attachment vector or recruitment interface when binding remains intact. Do not assume that inhibitor resistance necessarily predicts degrader resistance, or that degradation automatically bypasses every binding-site mutation.

E3 Ligase-Side Failures: The Recruitment Partner Is Missing or Compromised

The E3-binding element is part of a biological system, not simply another affinity handle. A target-binding degrader needs a functional recruitment partner in an appropriate cellular location. Expression, complex integrity, competing interactions, and localization should be evaluated separately rather than inferred from one positive binding assay.

I. Low or Absent E3 Ligase Expression in the Chosen Cell Model

When the recruited ligase or substrate receptor is absent or limiting, stronger target binding alone cannot correct the recruitment bottleneck. Kinetic modeling identifies E3 abundance as one contributor to degradation potency, but abundance should not be treated as a universal predictor independent of recruitment and ubiquitination efficiency.

• Check: Measure the recruited E3 component at the protein level in the actual assay cells. Use transcript data as supporting information. Include a functioning reference degrader that uses the same E3 system when a suitable reference and measurable target are available.
• Improve: Select a recruiter supported by the intended model's biology. E3 re-expression can help test a hypothesis, but successful degradation after artificial overexpression does not establish equivalent activity at endogenous expression.

An E3 ubiquitin ligase activity assay can complement abundance measurements when the key uncertainty is whether recruitment supports ubiquitin transfer.

II. Downregulation and Mutation of E3 Complex Components

Detectable recruiter-binding protein does not prove that the complete ubiquitination system is functional. Changes in scaffold proteins, adaptors, or other required components may prevent productive transfer. Acquired resistance to experimental E3-recruiting degraders has been linked to alterations in core ligase-complex components rather than changes in the targeted protein itself.

• Check: Compare responsive and resistant cells for relevant component abundance and sequence changes. Pair these data with target ubiquitination and a pathway-matched functional control. For cullin-based systems, assess activation-related defects where evidence points to them.
• Improve: Use component restoration or other controlled perturbations to test causality. Consider switching E3 systems only after confirming that the alternative machinery is functional and that the new degrader retains adequate exposure and target engagement.

III. Competition From Endogenous Substrates and Free Ligand Occupancy

Free recruiter ligands, co-dosed compounds, or breakdown products may occupy binding sites needed by a bifunctional degrader. Endogenous substrates can also compete for ligase processing capacity, but this is not necessarily competition at the small-molecule binding pocket. These possibilities should remain testable hypotheses, not default explanations for low activity.

• Check: Review compound composition, residual starting materials, treatment combinations, and detected metabolites. Test suspected competitors individually while monitoring degrader exposure and target engagement.
• Interpret: Competition by a free target or E3 ligand can support pathway involvement, but does not prove that endogenous substrate competition caused the original failure. Changes in viability or compound transport must also be excluded.
• Improve: Remove avoidable competing ligands and improve compound integrity. Investigate alternative recruitment strategies when competition is experimentally supported, rather than assuming that increasing degrader concentration will resolve it.

IV. Mismatch Between Recruited E3 Ligase and Target Compartment

The target and recruited E3 machinery need access to a shared cellular space. A ligase may be abundant overall but poorly positioned to act on a particular target pool. Compartment-restricted recruitment has been demonstrated experimentally, emphasizing that ligase choice can influence which cellular protein population is removed.

• Check: Compare target and E3 localization under the same experimental conditions. Use fraction-specific degradation measurements when whole-cell assays may conceal selective loss from only one pool.
• Improve: Choose a recruitment system compatible with the target compartment. Validate any engineered relocalization strategy separately, because altering protein location may also change the biological question being studied.

Colocalization is a feasibility check, not proof of productive recruitment. It should be followed by evidence of proximity, target ubiquitination, and actual protein loss.

Ternary Complex Failures: Why Strong Binary Binders Still Do Not Degrade

Binding the target and ligase separately does not establish that the same degrader can connect them productively. The combined assembly introduces additional geometric and interaction requirements. Structural studies show that induced protein-protein contacts can influence recruitment and selectivity, making the ternary complex a distinct experimental question rather than a predictable consequence of two strong binary affinities.

I. Missing or Negative Cooperativity at the Protein–Protein Interface

Positive cooperativity means that binding one partner favors recruitment of the other under the defined measurement conditions. Negative cooperativity makes this less favorable. However, the absence of positive cooperativity is not, by itself, degradation failure: effective degraders with noncooperative or negatively cooperative recruitment have been reported.

• Check: Measure binary and ternary interactions with compatible constructs and assay conditions. State how cooperativity is calculated, and evaluate complex formation together with dissociation behavior and target ubiquitination.
• Improve: Explore attachment points, target ligands, or recruiter orientations that produce a more useful interface. Rank designs by productive degradation, not by a cooperativity number alone.

The aim is sufficient productive recruitment in cells. A large proximity signal or favorable equilibrium measurement can still be uninformative if the complex does not support ubiquitin transfer.

II. Linker Length, Rigidity, and Exit Vector Problems

The linker controls more than distance. Its attachment vectors, flexibility, and local chemistry influence which relative protein orientations are accessible. A linker that is too restrictive may exclude useful arrangements, while additional length may introduce unproductive conformations or change cellular exposure. Neither shorter nor more rigid is automatically better.

• Check: Compare a focused analog matrix rather than changing length, recruiter, and warhead simultaneously. Track target binding, E3 binding, ternary behavior, and cellular exposure so that an apparent geometry improvement is not confused with better uptake.
• Improve: Vary one or two interpretable design features at a time, such as attachment site and linker length. Use structural models to prioritize experiments, then test the proposed arrangement experimentally.

Molecular dynamics simulation can explore conformational possibilities, but a plausible model should not be described as proof of a productive cellular complex.

III. Unproductive Complex Geometry and Poor Lysine Accessibility

A detectable ternary complex may position the target poorly for ubiquitin transfer. Studies comparing recruited ligase orientations show that binding and complex formation can be insufficient when the arrangement does not support productive target ubiquitination. Accessible lysine residues matter, but simply counting surface lysines does not establish degradability.

• Check: Measure target-associated ubiquitination under conditions that distinguish modification of the target from modification of its binding partners. Compare the timing of ubiquitination with subsequent target loss.
• Improve: Change the exit vector, bound target domain, linker, or E3 system when recruitment occurs without useful ubiquitination. Reassess binding and exposure after each change rather than attributing every improvement solely to lysine positioning.

When ubiquitination is present but degradation is weak: Extend the investigation downstream. Consider whether the modification supports proteasomal recognition, whether ubiquitin removal limits processing, and whether the target can be unfolded and processed. Target-dependent processing requirements mean that ubiquitination alone is not a final success criterion.

IV. The Hook Effect: Binary Complexes Outcompeting the Ternary Complex

At sufficiently high concentrations, a reversible bifunctional degrader can occupy target and E3 proteins in separate binary complexes, reducing the bridged ternary population. This can produce a loss of degradation at the upper end of a concentration series. The underlying three-body binding behavior depends on affinities, cooperativity, and available protein concentrations.

• Check: Extend the concentration series downward as well as upward. Compare degradation with ternary-complex behavior, solubility, and cell health to distinguish a hook effect from high-concentration artifacts.
• Improve: Work within the experimentally supported activity window and evaluate designs that preserve productive recruitment across a useful range. Do not discard a compound solely because a high-dose condition performs worse.

Not every degrader shows a measurable hook effect within practical assay conditions. The classical bifunctional explanation should not be applied automatically to molecular glues or other recruitment architectures.

Assay Design Failures: Why Degradation Results Can Be Misleading

Before concluding that a target resists degradation, confirm that the experiment could detect a meaningful response. The concentration range, sampling schedule, model, and readout should all be appropriate for the question. This is especially important when comparing studies performed with different constructs or endpoint definitions.

I. Concentration Ranges That Miss the Effective Window

A narrow concentration series may remain below the exposure needed for activity or include only concentrations where solubility, cell stress, or a hook effect complicates interpretation. A single high-dose condition is therefore a weak basis for declaring a degrader inactive.

• Check: Use a concentration series broad enough to resolve onset, effective concentrations, and any upper-range loss of activity. Include solvent-matched controls and confirm compound recovery and cell viability across that range.
• Improve: Add lower concentrations when high-dose results are unexpectedly weak. Report the measured D_max and the conditions supporting it. Do not force a monotonic concentration-response fit onto a clearly nonmonotonic dataset or assign a precise DC₅₀ to an unresolved response.

II. Time Points That Miss the Degradation Window

An early endpoint can precede measurable target depletion. A late endpoint may miss the initial response because synthesis or adaptation has restored protein abundance. Kinetic studies demonstrate that degradation onset, depth, and recovery can differ between targets and compounds, even when a single endpoint makes them appear similar.

• Check: Sample early, intermediate, and later phases of the response. Relate target abundance to compound persistence and, where relevant, cell-cycle state. Add a washout comparison when durability is part of the research objective.
• Improve: Compare compounds over matched observation periods. Distinguish a slow degrader from an inactive one, and a short-lived response from a failure to initiate degradation.

III. Cell Model Selection and Expression-Level Confounders

Overexpressed proteins, isolated domains, and tagged reporters are useful experimental tools, but they may not reproduce the abundance, localization, or interaction state of the endogenous target. Cell-state differences can also affect degradation: target-family profiling has demonstrated cell-cycle-dependent responses for particular proteins.

• Check: Confirm target and E3 expression, the relevant target isoform, and cell condition. Compare reporter results with endogenous protein measurements in a suitable model. Assess whether tagging or overexpression changes localization or baseline behavior.
• Improve: Prioritize models that answer the intended biological question. Use engineered systems to investigate mechanisms, but confirm that conclusions extend to the endogenous target before claiming that the degrader succeeds or fails in the relevant setting.

IV. Missing Mechanistic Controls and Off-Target Misinterpretation

Target loss, reporter loss, and reduced viability are different observations. A reporter may be quenched or directly inhibited; an antibody may measure only selected target species; reduced expression may lower protein abundance without induced destruction. Conversely, an insensitive or saturated detection method can conceal genuine partial degradation.

• Confirm protein loss: Combine complementary measurements, such as immunoblotting and targeted proteomics, when feasible. Verify assay range, target specificity, extraction recovery, and normalization before interpreting a negative result.
• Test pathway dependence: Use appropriate proteasome inhibition, E3 perturbation, and competition controls for the proposed mechanism. Include controls for the perturbations themselves because they can alter target abundance, protein synthesis, or cell health.
• Separate binding from degradation: Compare the active degrader with the parent ligand and a mechanistically impaired analog. PROTAC diastereomer design for negative controls can support this comparison where a stereochemical change selectively reduces recruitment.
• Check selectivity: Examine related proteins or broader proteomic changes when the phenotype cannot be explained by target depletion. A functional effect without demonstrable target loss should not be labeled successful target degradation.

Interpret controls together: An inactive analog is most informative when its exposure and target engagement remain comparable to the active molecule. Likewise, inhibitor-mediated rescue supports a proposed pathway but should be considered alongside recruitment, ubiquitination, and target-abundance evidence, not treated as definitive on its own.

Table 3. BOC Sciences Services for Protein Degrader Troubleshooting and Optimization.

Conclusion

Protein degrader troubleshooting is most useful when it identifies the step that separates a promising interaction from measurable target removal. Begin by confirming that the assay can detect the intended response. Then establish intact-compound exposure, cellular target engagement, a functional and accessible E3 system, productive recruitment, target ubiquitination, and protein loss. Examine resynthesis and recovery when depletion is incomplete or temporary.

The next design decision should follow the evidence. Exposure limitations call for property optimization; lost engagement calls for ligand or attachment-site changes; E3 defects call for recruitment reassessment; and nonproductive complexes call for geometric redesign. A single negative endpoint should not be used to declare the target inherently undegradable. BOC Sciences provides design, synthesis, and evaluation support to help turn ambiguous degradation results into a focused experimental and optimization plan.

Degrader Troubleshooting and Optimization Support at BOC Sciences

BOC Sciences supports research teams investigating weak, inconsistent, or short-lived protein degradation. Projects can begin with an existing compound, a small analog series, or a target with preliminary binding data. The initial scope can focus on the uncertainty that most directly affects the next decision, rather than requiring a complete development package.

Degrader Structure Analysis and Molecular Design

• Binding-site review: Use protein-ligand structure analysis to assess attachment vectors and potential disruption of target-binding contacts.
• Recruitment planning: Compare target accessibility, candidate E3 systems, and plausible ternary arrangements.
• Focused redesign: Prioritize structural changes that test the proposed failure mechanism, with clear comparisons between analogs.

Custom Degrader Synthesis and Focused Analog Libraries

• Matched analogs: Prepare compounds varying target-ligand attachment, linker chemistry, recruiter identity, or stereochemistry.
• Library support: Combine PROTAC libraries and linker libraries with hypothesis-driven custom synthesis.
• Compound characterization: Connect structural identity and analytical characterization with subsequent binding and degradation studies.

Ternary Complex, Ubiquitination, and Degradation Assays

• Mechanistic separation: Compare recruitment, target ubiquitination, and protein depletion rather than relying on one proximity readout.
• Assay components: Support suitable assay development with custom protein expression and purification.
• Response profiling: Evaluate concentration dependence, D_max, degradation kinetics, and recovery according to the project question.

Physicochemical and Cellular Evaluation

• Exposure assessment: Investigate solubility, stability, permeability, and cellular compound accumulation.
• Activity interpretation: Relate exposure to engagement and degradation while tracking cell health and model-specific differences.
• Selectivity assessment: Add PROTAC selectivity evaluation when related-target effects complicate interpretation.

Explore featured products that can expand your research options and accelerate your next discovery.

Access end-to-end service solutions that help bring efficiency, flexibility, and expertise to your research pipeline.

News

• Protein Degradation with New Chemical Modalities: Successful Strategies in Drug Discovery and Chemical Biology
• Degrader Building Blocks for Targeted Protein Degradation
• Recent Progress of PROTACs Targeting Non-enzymatic Functional Proteins
• Discovery of Molecular Glue Degraders

Technical Information

• Proteolysis-Targeting Chimeras (PROTAC)
• Targeted Protein Degradation: The Next Frontier in Drug Discovery
• Overview of 12 Targeted Protein Degradation Technologies
• Peptide and Small Molecule Based PROTACs Technology